MLYS vs PROK
MLYS: Mineralys is a clinical-stage biopharmaceutical company pursuing FDA approval of lorundrostat, a selective aldosterone synthase inhibitor targeting resistant hypertension and related cardiorenal diseases. PROK: ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in Phase 3 trials with FDA RMAT designation.
Side-by-side fundamentals
| Metric | MLYS | PROK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.01 | $1.53 | |
| Market cap as of 2026-07-23 | $2.4B | $462M | |
| Net margin as of 2026-07-23 | n/a | -8131.5% | |
| Operating margin as of 2026-07-23 | n/a | -18959.7% | |
| ROE as of 2026-07-23 | -27.9% | -28.1% | MLYS higher |
| ROA as of 2026-07-23 | -27.0% | -21.4% | PROK higher |
| Debt / equity as of 2026-07-23 | 0.00 | 5.40 | MLYS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +190.5% | |
| Beta as of 2026-07-23 | 0.59 | 1.81 | |
| 1-year return as of 2026-07-22 close | +102.1% | -49.8% | MLYS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.